The Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market would witness market growth of 2.9% CAGR during the forecast period (2022-2028).
Dietary factors, medications that can decrease LES competence, and obesity all help to cause the reflux of too much acid into the esophagus, whose mucosa is unfamiliar with this aggressive element. In recent years, the loss of the esophageal mucosa's protective qualities has been suggested as another factor in the pathophysiology of GERD. Several investigations have shown that most individuals with GERD, especially those with non-erosive reflux disease (NERD), who do not have mucosal lesions during endoscopy, have poor mucosal resistance of the esophagus.
Moreover, due to a compromised mucosal barrier, the development of dilated intercellular spaces (DIS) is frequent in individuals with genuine NERD and reflux hypersensitivity (RH). On the other hand, microscopic esophagitis, including DIS, is substantially less common in controls (15%) and patients with functional heartburn (FH) (13%), compared to patients with RH (65%) and patients with excess acid (77%), in patients with NERD.
Australians aged 18 and older who were overweight or obese made up 2 out of 3 (67%) of the population in 2017–18 (36% were overweight but not obese, and 31% were obese). 12.5 million adults, roughly. In comparison to women, males were more likely to be overweight (75% vs. 60%) and more likely to be obese (33% vs. 30%). Obesity is more prevalent in older age groups; 16% of individuals between the ages of 18 and 24 and 41% of persons between the ages of 65 and 74 were obese. Women were more likely than males to have a waist circumference significantly related to an elevated risk of developing chronic illnesses (46% of women versus 36% of men). This will expedite the market's growth in the coming years.
The China market dominated the Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $441.5 Million by 2028. The Japan market is estimated to grow a CAGR of 2.3% during (2022 - 2028). Additionally, The India market would experience a CAGR of 3.6% during (2022 - 2028).
Based on Type, the market is segmented into Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Gastroesophageal Reflux Disease Therapeutics Market is Projected to reach USD 5.6 Billion by 2028, at a CAGR of 2.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).
Scope of the Study
Market Segments Covered in the Report:
By Type
- Antacids
- Proton Pump Inhibitors (PPIs)
- H2 Receptor Blockers
- Pro-kinetic Agents
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Eisai Co., Ltd.
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Ironwood Pharmaceuticals, Inc.
- Johnson & Johnson
- Medigus Ltd.
- Sebela Pharmaceuticals
- Phathom Pharmaceuticals, Inc.
- Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, by Type
1.4.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type
3.1 Asia Pacific Antacids Market by Country
3.2 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country
3.3 Asia Pacific H2 Receptor Blockers Market by Country
3.4 Asia Pacific Pro-kinetic Agents Market by Country
Chapter 4. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country
4.1 China Gastroesophageal Reflux Disease Therapeutics Market
4.1.1 China Gastroesophageal Reflux Disease Therapeutics Market by Type
4.2 Japan Gastroesophageal Reflux Disease Therapeutics Market
4.2.1 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type
4.3 India Gastroesophageal Reflux Disease Therapeutics Market
4.3.1 India Gastroesophageal Reflux Disease Therapeutics Market by Type
4.4 South Korea Gastroesophageal Reflux Disease Therapeutics Market
4.4.1 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type
4.5 Singapore Gastroesophageal Reflux Disease Therapeutics Market
4.5.1 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type
4.6 Malaysia Gastroesophageal Reflux Disease Therapeutics Market
4.6.1 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type
4.7 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
4.7.1 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type
Chapter 5. Company Profiles
5.1 Takeda Pharmaceutical Company Limited
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Regional Analysis
5.1.4 Research & Development Expense
5.2 AstraZeneca PLC
5.2.1 Company Overview
5.2.2 Financial Analysis
5.2.3 Regional Analysis
5.2.4 Research & Development Expenses
5.3 GlaxoSmithKline PLC (GSK)
5.3.1 Company Overview
5.3.2 Financial Analysis
5.3.3 Segmental and Regional Analysis
5.3.4 Research & Development Expense
5.4 Johnson & Johnson
5.4.1 Company Overview
5.4.2 Financial Analysis
5.4.3 Segmental &Regional Analysis
5.4.4 Research & Development Expenses
5.5 Ironwood Pharmaceuticals, Inc.
5.5.1 Company Overview
5.5.2 Financial Analysis
5.5.3 Regional Analysis
5.5.4 Research & Development Expenses
5.6 Eisai Co., Ltd.
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental and Regional Analysis
5.6.4 Research & Development Expenses
5.7 Medigus Ltd.
5.7.1 Company Overview
5.7.2 Financial Analysis
5.7.3 Segmental and Regional Analysis
5.7.4 Research & Development Expenses
5.8 Sebela Pharmaceuticals
5.8.1 Company Overview
5.8.2 Recent strategies and developments:
5.8.2.1 Partnerships, Collaborations, and Agreements:
5.9 Phathom Pharmaceuticals, Inc.
5.9.1 Company Overview
5.9.2 Research & Development Expenses
5.9.3 Recent strategies and developments:
5.9.3.1 Partnerships, Collaborations, and Agreements:
5.10. Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
5.10.1 Company Overview
5.10.2 Recent strategies and developments:
5.10.2.1 Product Launches and Product Expansions:
TABLE 1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 3 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 4 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 5 Asia Pacific Antacids Market by Country, 2018 - 2021, USD Million
TABLE 6 Asia Pacific Antacids Market by Country, 2022 - 2028, USD Million
TABLE 7 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
TABLE 8 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
TABLE 9 Asia Pacific H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
TABLE 10 Asia Pacific H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
TABLE 11 Asia Pacific Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
TABLE 12 Asia Pacific Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
TABLE 13 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
TABLE 14 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
TABLE 15 China Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 16 China Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 17 China Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 18 China Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 19 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 20 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 21 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 22 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 23 India Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 24 India Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 25 India Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 26 India Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 27 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 28 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 29 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 30 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 31 Singapore Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 32 Singapore Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 33 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 34 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 35 Malaysia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 36 Malaysia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 37 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 38 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 39 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 40 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 41 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 42 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 43 Key Information – Takeda Pharmaceutical Company Limited
TABLE 44 KEY INFORMATION – AstraZeneca PLC
TABLE 45 Key Information – GlaxoSmithKline PLC
TABLE 46 Key information –Johnson & Johnson
TABLE 47 Key Information – Ironwood Pharmaceuticals, Inc.
TABLE 48 Key Information – Eisai Co., Ltd.
TABLE 49 Key Information – Medigus Ltd.
TABLE 50 Key Information – Sebela Pharmaceuticals
TABLE 51 Key Information – Phathom Pharmaceuticals, Inc.
TABLE 52 Key Information – Camber Pharmaceuticals, Inc.
List of Figures
FIG 1 Methodology for the research